Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025PharmaciaOpen Access

Multi-target monoamine oxidase-B (MAO-B) inhibitors in the treatment of Parkinson’s disease

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEmilio MateevEPEkaterina PavlovaSKStefan Kostov

Discussion

Loading...

Member takes

Overview

This review highlights recent developments in MAO-B inhibitors for Parkinson's disease, suggesting new multi-target treatment options.

Key Points

  • Multi-target drugs show promise in treating parkinson's disease through diverse biological pathways.
  • The review indicates that MAO-B inhibitors are key in current treatment strategies for parkinson's disease.
  • The paper analyzes how chemical structure relates to biological activity in multi-target drug compounds.
  • Current paradigms in neuropharmacology favor multitarget-directed ligands for complex neurodegenerative conditions.

Cite This Study

Mateev et al. (2025) studied this question.

synapsesocial.com/papers/68d41eca713b0b5dfea67641https://doi.org/10.3897/pharmacia.72.e164727
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson’s Disease: A Brief Review2025
  2. 2Design, synthesis, investigation, and biological activity assessments of <i>n</i>-allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents2025
  3. 3Target-based Virtual Screening of Natural Compounds as Promising Anti-Parkinson’s Agents2025
  4. 4Targeting MAO-B selectivity: computational screening, docking, and molecular dynamics insights.2025 · 5 citations
  5. 5Pharmacophore-Based Virtual Screening of Alkaloids and Flavonoids for Designing Drugs with Inhibitory Activity on the Enzyme Monoamine Oxidase B2025